| Indicators | Browse All

LeonaBio, Inc. (LONA)

Healthcare | Biotechnology | Bothell, United States | NasdaqCM
9.76 USD +0.16 (1.667%) ⇧ (July 13, 2026, 4 p.m. EDT)

Short-term:★★⯪☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 3:09 a.m. EDT

The immediate outlook is neutral-to-slightly-bearish as the stock trades near its 50-day average despite a recent bounce off the lows, offering no clear high-conviction entry for a momentum play given the weak statistical forecast. However, the long-term investment case is severely compromised; the business has suffered a catastrophic structural decline, dropping nearly 96% over the last four years with a massive 87% collapse in the most recent year, signaling deep fundamental deterioration rather than a temporary setback. There is no dividend income to offset these risks, making this a speculative biotech name with a fortress-like balance sheet that cannot mask the reality of a failing commercial trajectory.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoARIMA ✓0.098721
AutoETS0.098721
MSTL0.101827
AutoTheta0.138392

Forecast horizon: 45 days | Selected: AutoARIMA

Forecast Reliability
Score 36%
H-stat 0.08
Ljung-Box p 0.000
Jarque-Bera p 0.354
Excess Kurtosis -0.78
Attribute Value
Sector Healthcare
Debt to Equity Ratio 1.402
Market Cap 91,680,696
Beta 2.02
Previous Name Athira Pharma, Inc.
Website https://www.leonabio.com

Info Dump

Attribute Value
52 Week Change 1.3880596
Address1 18,706 North Creek Parkway
Address2 Suite 104
All Time High 347.9
All Time Low 2.2
Ask 9.51
Ask Size 3
Audit Risk 10
Average Daily Volume10 Day 31,850
Average Daily Volume3 Month 31,988
Average Volume 31,988
Average Volume10Days 31,850
Beta 2.019
Bid 8.64
Bid Size 1
Board Risk 6
Book Value 5.249
City Bothell
Compensation As Of Epoch Date 1,767,139,200
Compensation Risk 7
Country United States
Crypto Tradeable 0
Currency USD
Current Price 9.76
Current Ratio 10.381
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 10.1045
Day Low 8.901
Debt To Equity 1.402
Display Name LeonaBio
Earnings Timestamp End 1,786,046,400
Earnings Timestamp Start 1,786,046,400
Ebitda -41,825,000
Ebitda Margins 0.0
Enterprise To Ebitda -0.59
Enterprise Value 24,692,696
Eps Trailing Twelve Months -24.09
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 9.1872
Fifty Day Average Change 0.57280064
Fifty Day Average Change Percent 0.062347688
Fifty Two Week Change Percent 138.80597
Fifty Two Week High 14.21
Fifty Two Week High Change -4.45
Fifty Two Week High Change Percent -0.31315973
Fifty Two Week Low 3.24
Fifty Two Week Low Change 6.5200005
Fifty Two Week Low Change Percent 2.0123458
Fifty Two Week Range 3.24 - 14.21
Financial Currency USD
First Trade Date Milliseconds 1,600,435,800,000
Float Shares 5,616,852
Free Cashflow -17,871,624
Full Exchange Name NasdaqCM
Full Time Employees 19
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,782,864,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.04507
Held Percent Institutions 0.70413
Implied Shares Outstanding 9,393,514
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,758,153,600
Last Split Factor 1:10
Long Business Summary LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of diabetic neuropathy, which is in phase 1 clinical trial; and ATH-1017 for the treatment of Alzheimer's disease and Parkinson's disease, which is in phase 2 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Long Name LeonaBio, Inc.
Market us_market
Market Cap 91,680,696
Market State PRE
Max Age 86,400
Message Board Id finmb_266015004
Most Recent Quarter 1,774,915,200
Name Change Date 2,026-07-13
Net Income To Common -129,414,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 93,841,204
Number Of Analyst Opinions 2
Open 9.31
Operating Cashflow -51,967,000
Operating Margins 0.0
Overall Risk 8
Payout Ratio 0.0
Phone 425 620 8501
Prev Name Athira Pharma, Inc.
Previous Close 9.6
Price Hint 2
Price To Book 1.8594018
Profit Margins 0.0
Quick Ratio 10.153
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 0.16
Regular Market Change Percent 1.66667
Regular Market Day High 10.1045
Regular Market Day Low 8.901
Regular Market Day Range 8.901 - 10.1045
Regular Market Open 9.31
Regular Market Previous Close 9.6
Regular Market Price 9.76
Regular Market Time 1,783,972,801
Regular Market Volume 315,755
Return On Assets -0.46464002
Return On Equity -2.9876401
Sand P52 Week Change 0.20847368
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 8
Shares Outstanding 9,393,514
Shares Percent Shares Out 0.006
Shares Short 56,070
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 56,592
Short Name LeonaBio, Inc.
Short Percent Of Float 0.0076
Short Ratio 3.04
Source Interval 15
State WA
Symbol LONA
Target High Price 20.0
Target Low Price 16.0
Target Mean Price 18.0
Target Median Price 18.0
Total Cash 67,679,000
Total Cash Per Share 7.205
Total Debt 691,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -24.09
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 6.766725
Two Hundred Day Average Change 2.9932752
Two Hundred Day Average Change Percent 0.44235212
Type Disp Equity
Volume 315,755
Website https://www.leonabio.com
Zip 98,011